150 related articles for article (PubMed ID: 25409898)
1. An evaluation of a multi-site community pharmacy-based chronic obstructive pulmonary disease support service.
Wright D; Twigg M; Barton G; Thornley T; Kerr C
Int J Pharm Pract; 2015 Feb; 23(1):36-43. PubMed ID: 25409898
[TBL] [Abstract][Full Text] [Related]
2. Chronic obstructive pulmonary disease case finding by community pharmacists: a potential cost-effective public health intervention.
Wright D; Twigg M; Thornley T
Int J Pharm Pract; 2015 Feb; 23(1):83-5. PubMed ID: 25371146
[TBL] [Abstract][Full Text] [Related]
3. Medication reviews in the community: results of a randomized, controlled effectiveness trial.
Sorensen L; Stokes JA; Purdie DM; Woodward M; Elliott R; Roberts MS
Br J Clin Pharmacol; 2004 Dec; 58(6):648-64. PubMed ID: 15563363
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.
Ágh T; Inotai A; Mészáros Á
Respiration; 2011; 82(4):328-34. PubMed ID: 21454953
[TBL] [Abstract][Full Text] [Related]
5. Impact of community pharmacists in COPD management: Inhalation technique and medication adherence.
Hesso I; Gebara SN; Kayyali R
Respir Med; 2016 Sep; 118():22-30. PubMed ID: 27578467
[TBL] [Abstract][Full Text] [Related]
6. Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service.
Elliott RA; Boyd MJ; Salema NE; Davies J; Barber N; Mehta RL; Tanajewski L; Waring J; Latif A; Gkountouras G; Avery AJ; Chuter A; Craig C
BMJ Qual Saf; 2016 Oct; 25(10):747-58. PubMed ID: 26647412
[TBL] [Abstract][Full Text] [Related]
7. The association between pharmacy refill-adherence metrics and healthcare utilisation: a prospective cohort study of older hypertensive adults.
Dillon P; Smith SM; Gallagher P; Cousins G
Int J Pharm Pract; 2019 Oct; 27(5):459-467. PubMed ID: 30968988
[TBL] [Abstract][Full Text] [Related]
8. COPD management in primary care: an observational, community pharmacy-based study.
Mehuys E; Boussery K; Adriaens E; Van Bortel L; De Bolle L; Van Tongelen I; Remon JP; Brusselle G
Ann Pharmacother; 2010 Feb; 44(2):257-66. PubMed ID: 20103611
[TBL] [Abstract][Full Text] [Related]
9. Building capacity in primary care: the implementation of a novel 'Pharmacy First' scheme for the management of UTI, impetigo and COPD exacerbation.
Stewart F; Caldwell G; Cassells K; Burton J; Watson A
Prim Health Care Res Dev; 2018 Nov; 19(6):531-541. PubMed ID: 29362007
[TBL] [Abstract][Full Text] [Related]
10. An integrated care facilitation model improves quality of life and reduces use of hospital resources by patients with chronic obstructive pulmonary disease and chronic heart failure.
Bird S; Noronha M; Sinnott H
Aust J Prim Health; 2010; 16(4):326-33. PubMed ID: 21138701
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
Boyd KA; Briggs AH
Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
[TBL] [Abstract][Full Text] [Related]
12. Promoting Community Pharmacy Practice for Chronic Obstructive Pulmonary Disease (COPD) Management: A Systematic Review and Logic Model.
Hu Y; Yao D; Ung COL; Hu H
Int J Chron Obstruct Pulmon Dis; 2020; 15():1863-1875. PubMed ID: 32821091
[TBL] [Abstract][Full Text] [Related]
13. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
14. Supporting patients with long-term conditions in the community: Evaluation of the Greater Manchester Community Pharmacy Care Plan Service.
Seston EM; Magola E; Bower P; Chen LC; Jacobs S; Lewis PJ; Steinke D; Willis SC; Schafheutle EI
Health Soc Care Community; 2020 Sep; 28(5):1671-1687. PubMed ID: 32285994
[TBL] [Abstract][Full Text] [Related]
15. How to enhance public health service utilization in community pharmacy?: general public and health providers' perspectives.
Saramunee K; Krska J; Mackridge A; Richards J; Suttajit S; Phillips-Howard P
Res Social Adm Pharm; 2014; 10(2):272-84. PubMed ID: 23089293
[TBL] [Abstract][Full Text] [Related]
16. COPD Management in Community Pharmacy Results in Improved Inhaler Use, Immunization Rate, COPD Action Plan Ownership, COPD Knowledge, and Reductions in Exacerbation Rates.
Fathima M; Bawa Z; Mitchell B; Foster J; Armour C; Saini B
Int J Chron Obstruct Pulmon Dis; 2021; 16():519-533. PubMed ID: 33688177
[TBL] [Abstract][Full Text] [Related]
17. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease.
Sridhar M; Taylor R; Dawson S; Roberts NJ; Partridge MR
Thorax; 2008 Mar; 63(3):194-200. PubMed ID: 17901162
[TBL] [Abstract][Full Text] [Related]
18. Adherence and healthcare utilization among older adults with COPD and depression.
Albrecht JS; Khokhar B; Huang TY; Wei YJ; Harris I; Moyo P; Hur P; Lehmann SW; Netzer G; Simoni-Wastila L
Respir Med; 2017 Aug; 129():53-58. PubMed ID: 28732836
[TBL] [Abstract][Full Text] [Related]
19. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial.
Gallefoss F
Patient Educ Couns; 2004 Mar; 52(3):259-66. PubMed ID: 14998595
[TBL] [Abstract][Full Text] [Related]
20. Drug-related problems and pharmacist interventions in a cohort of patients with asthma and chronic obstructive pulmonary disease.
Apikoglu-Rabus S; Yesilyaprak G; Izzettin FV
Respir Med; 2016 Nov; 120():109-115. PubMed ID: 27817807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
